Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-25 4:23 pm Sale |
2024-09-30 | 13G | Protalix BioTherapeutics, Inc. PLX |
WHITEBOX ADVISORS LLC | 0 0.000% |
-2,816,108 (Position Closed) |
Filing History |
| 2024-01-02 06:36 am Sale |
2023-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
NACHT MARIUS | 2,208,913 2.900% |
-607,988 (-21.58%) |
Filing History |
| 2023-01-03 06:01 am Unchanged |
2022-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
NACHT MARIUS | 2,816,901 5.300% |
0 (Unchanged) |
Filing History |
| 2022-06-09 2:52 pm Purchase |
2022-05-13 | 13G | Protalix BioTherapeutics, Inc. PLX |
WHITEBOX ADVISORS LLC | 2,816,108 5.650% |
2,816,108 (New Position) |
Filing History |
| 2022-02-14 3:14 pm Purchase |
2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,414,487 5.030% |
2,414,487 (New Position) |
Filing History |
| 2022-02-11 08:19 am Sale |
2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 0 0.000% |
-6,063,194 (Position Closed) |
Filing History |
| 2022-01-31 07:16 am Sale |
2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
NACHT MARIUS | 2,816,901 5.800% |
-570,421 (-16.84%) |
Filing History |
| 2021-07-30 06:02 am Sale |
2021-06-30 | 13G | Protalix BioTherapeutics, Inc. PLX |
BURRAGE CAPITAL MANAGEMENT LLC | 0 0.000% |
-2,470,332 (Position Closed) |
Filing History |
| 2021-06-15 09:19 am Sale |
2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% |
-2,521,914 (-55.35%) |
Filing History |
| 2021-02-16 12:06 pm Purchase |
2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX |
Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% |
1,267,940 (+38.56%) |
Filing History |
| 2021-02-16 10:03 am Purchase |
2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,091,176 3.200% |
150,000 (+15.94%) |
Filing History |
| 2021-02-12 12:00 pm Purchase |
2020-12-04 | 13G | Protalix BioTherapeutics, Inc. PLX |
BURRAGE CAPITAL MANAGEMENT LLC | 2,470,332 7.410% |
2,470,332 (New Position) |
Filing History |
| 2021-02-09 08:19 am Purchase |
2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 6,063,194 9.990% |
2,730,440 (+81.93%) |
Filing History |
| 2021-02-08 11:51 am Unchanged |
2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
CITIGROUP INC C |
921,412 2.700% |
0 (Unchanged) |
Filing History |
| 2021-02-08 06:08 am Purchase |
2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
NACHT MARIUS | 3,387,322 9.990% |
99,231 (+3.02%) |
Filing History |
| 2020-11-24 06:04 am Purchase |
2020-03-18 | 13G | Protalix BioTherapeutics, Inc. PLX |
NACHT MARIUS | 3,288,091 9.900% |
3,288,091 (New Position) |
Filing History |